Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Roche To Acquire Anadys | Contract Pharma

What are you searching for?

Sign in
Breaking News

Roche To Acquire Anadys

Gains Setrobuvir, a direct-acting antiviral compound

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche has entered into a definitive merger agreement for Roche to acquire Anadys Pharmaceuticals, Inc. for $230 million in cash. Anadys, based in San-Diego, CA, develops oral, small molecule therapeutics for the potential treatment of hepatitis C virus (HCV) infection. Anadys’ most advanced drug candidate, Setrobuvir (ANA598), is a direct-acting antiviral compound currently in a Phase II study in combination with Roche’s pegylated interferon (Pegasys) and ribavirin (Copegus).

Jean-Jacques Garaud, global head of Roche Pharma Research and Early Development, said, “This acquisition augments our already strong HCV portfolio. Our aim is to offer physicians and hepatitis patients a powerful combination of therapies that bring us closer to a cure, even without the use of interferon. Anadys’ compounds provide additional modes of action that could lead to interferon-free treatment regimens without viral resistance.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters